News Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP) Feb 22, 2023
Whitepapers Implementing Decentralized Clinical Trials: Strategic Design Vs. “Retrofitting” Feb 16, 2023